| Identification | Back Directory | [Name]
Velagliflozin | [CAS]
946525-65-1 | [Synonyms]
Velagliflozin
Benzonitrile, 2-[(4-cyclopropylphenyl)methyl]-4-β-D-glucopyranosyl- | [Molecular Formula]
C23H25NO5 | [MDL Number]
MFCD31692353 | [MOL File]
946525-65-1.mol | [Molecular Weight]
395.46 |
| Chemical Properties | Back Directory | [Boiling point ]
648.6±55.0 °C(Predicted) | [density ]
1.39±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
13.18±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity. | [in vivo]
Velagliflozin (1 mg/kg; p.o.; single dose) increases cholesterol, albumin, beta-hydroxybutyrate (BHB), nonesterified fatty acids (NEFA), and urinary glucose excretion, and decreases respiratory exchange ratio in cats[1].
Velagliflozin (0.3 mg/kg; p.o.; once daily for 18 d) is well tolerated and can improve insulin disorders and prevent laminitis in ponies by reducing the high insulin response of dietary non-structural carbohydrates (NSC)[2].
| [IC 50]
SGLT2 | [storage]
Store at -20°C | [References]
[1] Hoenig M, et al. Effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats. J Vet Pharmacol Ther. 2018 Apr;41(2):266-273. DOI:10.1111/jvp.12467
[2] Meier A, et al. The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies. PLoS One. 2018 Sep 13;13(9):e0203655. DOI:10.1371/journal.pone.0203655 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|